<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-30207" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Tinea Cruris</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Pippin</surname>
            <given-names>Micah M.</given-names>
          </name>
          <aff>LSUHSC Shreveport</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Madden</surname>
            <given-names>Michael L.</given-names>
          </name>
          <aff>LSUHSC / Rapides Regional MC</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Das</surname>
            <given-names>Moushumi</given-names>
          </name>
          <aff>University of Auckland</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Micah Pippin declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Michael Madden declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Moushumi Das declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>17</day>
          <month>8</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-30207.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Tinea cruris, also known as jock itch, is an infection involving the genital, pubic, perineal, and perianal skin caused by pathogenic fungi known as dermatophytes. The evaluation and treatment of tinea cruris are discussed in the activity. This activity reviews the role of the healthcare team in improving care for patients with this condition. The activity will also highlight evidence-based therapeutics and lifestyle modifications to avoid common mistakes and mistreatments associated with the management of dermatophyte infections.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the etiology of tinea cruris.</p></list-item><list-item><p>Outline the evaluation of tinea cruris.</p></list-item><list-item><p>Review the treatment options available for tinea cruris.</p></list-item><list-item><p>Describe interprofessional team strategies to improve the management of patients affected by tinea cruris.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=30207&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=30207">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-30207.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Tinea cruris, also known as jock itch, is an infection involving the genital, pubic, perineal, and perianal skin caused by pathogenic fungi known as dermatophytes.<xref ref-type="bibr" rid="article-30207.r1">[1]</xref><xref ref-type="bibr" rid="article-30207.r2">[2]</xref><xref ref-type="bibr" rid="article-30207.r3">[3]</xref><xref ref-type="bibr" rid="article-30207.r4">[4]</xref><xref ref-type="bibr" rid="article-30207.r5">[5]</xref>&#x000a0;These dermatophytes affect keratinized structures such as hair and the epidermis' stratum corneum resulting in a characteristic rash. Intertriginous areas are hospitable environments for fungus, with sweating, maceration, and alkaline pH being responsible for the groin's predilection for infection.<xref ref-type="bibr" rid="article-30207.r1">[1]</xref><xref ref-type="bibr" rid="article-30207.r3">[3]</xref><xref ref-type="bibr" rid="article-30207.r4">[4]</xref><xref ref-type="bibr" rid="article-30207.r5">[5]</xref></p>
        <p>While tinea infections are often classified by the location of the body affected, they are also organized&#x000a0;according to the responsible organism's primary source and mode of transmission.<xref ref-type="bibr" rid="article-30207.r3">[3]</xref> Geophilic, zoophilic, and anthropophilic fungi are found in and transmitted by soil, animals, and humans, respectively.<xref ref-type="bibr" rid="article-30207.r1">[1]</xref><xref ref-type="bibr" rid="article-30207.r3">[3]</xref><xref ref-type="bibr" rid="article-30207.r6">[6]</xref><xref ref-type="bibr" rid="article-30207.r7">[7]</xref>&#x000a0;Autoinfection of dermatophytes is also possible and especially crucial in tinea cruris as foot-to-groin spread can occur.<xref ref-type="bibr" rid="article-30207.r1">[1]</xref></p>
      </sec>
      <sec id="article-30207.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Tinea cruris is caused by dermatophytes belonging to three genera, <italic toggle="yes">Trichophyton</italic>, <italic toggle="yes">Epidermophyton</italic>, and <italic toggle="yes">Microsporum</italic>.<xref ref-type="bibr" rid="article-30207.r5">[5]</xref>
<italic toggle="yes">Trichophyton rubrum</italic> has been isolated most commonly and remains the most frequent cause of tinea cruris worldwide; however, most studies do recognize the increasing prevalence of Trichophyton mentagrophytes and other organisms in certain regions.<xref ref-type="bibr" rid="article-30207.r1">[1]</xref><xref ref-type="bibr" rid="article-30207.r2">[2]</xref><xref ref-type="bibr" rid="article-30207.r3">[3]</xref><xref ref-type="bibr" rid="article-30207.r4">[4]</xref><xref ref-type="bibr" rid="article-30207.r7">[7]</xref>&#x000a0;Several risk factors have been identified that predispose an individual to tinea cruris, including excessive perspiration, occlusive clothing, improper hygiene, diabetes mellitus, immunocompromise, and lower socioeconomic status.<xref ref-type="bibr" rid="article-30207.r1">[1]</xref><xref ref-type="bibr" rid="article-30207.r2">[2]</xref><xref ref-type="bibr" rid="article-30207.r3">[3]</xref><xref ref-type="bibr" rid="article-30207.r6">[6]</xref></p>
        <p>Athletes, especially those involved in contact sports, may be more likely to contract tinea infections.<xref ref-type="bibr" rid="article-30207.r1">[1]</xref> Genetics can also make a patient more susceptible to dermatophytes.<xref ref-type="bibr" rid="article-30207.r3">[3]</xref><xref ref-type="bibr" rid="article-30207.r6">[6]</xref> Of all these factors, perspiration appears to be the most influential variable in the development of infection.<xref ref-type="bibr" rid="article-30207.r1">[1]</xref><xref ref-type="bibr" rid="article-30207.r8">[8]</xref>&#x000a0;In India, an area affected disproportionately often with dermatophytes, a study was conducted in response to the increasing frequency of and decreased treatment efficacy for local tinea infections.<xref ref-type="bibr" rid="article-30207.r9">[9]</xref> Diabetes mellitus, family members with tinea, and personal history of cooking food were found to be positively associated with chronic and relapsing disease.<xref ref-type="bibr" rid="article-30207.r9">[9]</xref></p>
      </sec>
      <sec id="article-30207.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Cutaneous mycoses, including tinea cruris, affect 20 to 25 percent of the world's population.<xref ref-type="bibr" rid="article-30207.r3">[3]</xref><xref ref-type="bibr" rid="article-30207.r10">[10]</xref> Developing and tropical countries have an increased prevalence of dermatophyte infections secondary to high temperatures and increased humidity.<xref ref-type="bibr" rid="article-30207.r1">[1]</xref><xref ref-type="bibr" rid="article-30207.r11">[11]</xref> In the United States, there have been an estimated 29.4 million cases of superficial fungal infections and over 51 million reported physician visits.<xref ref-type="bibr" rid="article-30207.r6">[6]</xref> Adolescent and adult males comprise the majority of patients seen for tinea cruris and are affected by the disorder with increased frequency.<xref ref-type="bibr" rid="article-30207.r1">[1]</xref><xref ref-type="bibr" rid="article-30207.r2">[2]</xref><xref ref-type="bibr" rid="article-30207.r11">[11]</xref> Worldwide increases in the occurrence of dermatophytoses and the discovery of recalcitrant infections have caused global concern.<xref ref-type="bibr" rid="article-30207.r3">[3]</xref><xref ref-type="bibr" rid="article-30207.r4">[4]</xref><xref ref-type="bibr" rid="article-30207.r5">[5]</xref><xref ref-type="bibr" rid="article-30207.r9">[9]</xref></p>
      </sec>
      <sec id="article-30207.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>A simplified explanation of the complex and not well-understood pathophysiology of dermatophytes includes the organism's use of proteinases to digest keratin found in the skin's stratum corneum.<xref ref-type="bibr" rid="article-30207.r6">[6]</xref><xref ref-type="bibr" rid="article-30207.r12">[12]</xref><xref ref-type="bibr" rid="article-30207.r7">[7]</xref></p>
      </sec>
      <sec id="article-30207.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>While not always necessary for diagnosis, a potassium hydroxide (KOH) preparation may reveal histology consistent with dermatophyte infections.<xref ref-type="bibr" rid="article-30207.r1">[1]</xref><xref ref-type="bibr" rid="article-30207.r2">[2]</xref><xref ref-type="bibr" rid="article-30207.r3">[3]</xref> Characteristic findings include branching or non-branching septate hyphae and possible arthroconidiospores.<xref ref-type="bibr" rid="article-30207.r2">[2]</xref><xref ref-type="bibr" rid="article-30207.r3">[3]</xref></p>
      </sec>
      <sec id="article-30207.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Patients with tinea cruris present complaining of a pruritic rash involving the groin.<xref ref-type="bibr" rid="article-30207.r1">[1]</xref><xref ref-type="bibr" rid="article-30207.r2">[2]</xref> The area may be irritated and painful if maceration is present, and secondary infections may result in inflammation and discomfort.<xref ref-type="bibr" rid="article-30207.r2">[2]</xref>&#x000a0;Duration of symptoms, previous occurrences, similar rashes in other locations, and past treatments should be elucidated. Individuals should be questioned about any history of diabetes, immunocompromise, renal disease, or hepatic dysfunction.<xref ref-type="bibr" rid="article-30207.r13">[13]</xref>&#x000a0;Clinicians should inquire about excessive sweating, wardrobe changes, and personal hygiene habits. A review of the patient's environmental and occupation exposures, including people, pets, animals, and contaminated soil, may be contributory.<xref ref-type="bibr" rid="article-30207.r13">[13]</xref></p>
        <p>On physical examination, an erythematous, scaly, annular plaque with a raised leading edge and central clearing can be visualized, extending anywhere from the groin, upper thigh, and perineum to the perianal region.<xref ref-type="bibr" rid="article-30207.r1">[1]</xref><xref ref-type="bibr" rid="article-30207.r2">[2]</xref></p>
      </sec>
      <sec id="article-30207.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>In most cases, tinea cruris can be diagnosed clinically; however, several tests exist to investigate a rash of the groin with unknown etiology.<xref ref-type="bibr" rid="article-30207.r1">[1]</xref><xref ref-type="bibr" rid="article-30207.r2">[2]</xref><xref ref-type="bibr" rid="article-30207.r3">[3]</xref> Potassium hydroxide (KOH) preparations, skin biopsy with periodic acid-Schiff (PAS) stain, and fungal cultures on Sabouraud&#x02019;s agar media can be utilized when the diagnosis is in question or the case of recurrent or recalcitrant episodes.<xref ref-type="bibr" rid="article-30207.r1">[1]</xref><xref ref-type="bibr" rid="article-30207.r2">[2]</xref><xref ref-type="bibr" rid="article-30207.r3">[3]</xref></p>
        <p>In general, the sample should be obtained from the leading edge of the lesion to ensure an adequate collection of infected scales.<xref ref-type="bibr" rid="article-30207.r1">[1]</xref>&#x000a0;Potassium hydroxide (KOH) mounts are generally procured with a scalpel scraping technique; however, new studies have indicated that utilizing a cellophane adhesive tape method may simplify the collection process, facilitate transportation, provide a higher quality sample, and improve slide preservation time.<xref ref-type="bibr" rid="article-30207.r14">[14]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-30207.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Antifungals utilized in treating dermatophytoses, including tinea cruris, target the synthesis of ergosterol, a vital component of fungal plasma membranes.<xref ref-type="bibr" rid="article-30207.r4">[4]</xref> Management strategies are similar worldwide; however, some countries have specific guidelines based on their region's fungal profile.<xref ref-type="bibr" rid="article-30207.r6">[6]</xref> Topical therapies are effective and usually preferred.<xref ref-type="bibr" rid="article-30207.r2">[2]</xref><xref ref-type="bibr" rid="article-30207.r4">[4]</xref><xref ref-type="bibr" rid="article-30207.r6">[6]</xref>&#x000a0;Allylamines (terbinafine, butenafine, naftifine) and azoles (clotrimazole, miconazole, sulconazole, oxiconazole, econazole, ketoconazole) are the mainstays of topical treatment regimens. They are generally prescribed once or twice daily for two to four weeks.<xref ref-type="bibr" rid="article-30207.r1">[1]</xref><xref ref-type="bibr" rid="article-30207.r3">[3]</xref><xref ref-type="bibr" rid="article-30207.r6">[6]</xref></p>
        <p>Deciding which agent to use should be based on patient compliance, cost, and medication accessibility, as there is insufficient data to directly compare the effectiveness of individual drugs and classes.<xref ref-type="bibr" rid="article-30207.r8">[8]</xref><xref ref-type="bibr" rid="article-30207.r15">[15]</xref><xref ref-type="bibr" rid="article-30207.r16">[16]</xref><xref ref-type="bibr" rid="article-30207.r13">[13]</xref>&#x000a0;Allylamines have a potentially shorter treatment timeline, have demonstrated lower relapse rates, and their metabolism is independent of the cytochrome p450 system.<xref ref-type="bibr" rid="article-30207.r8">[8]</xref><xref ref-type="bibr" rid="article-30207.r13">[13]</xref>&#x000a0;Azoles are not as costly as allylamines but often require a longer treatment duration.<xref ref-type="bibr" rid="article-30207.r8">[8]</xref> One newer topical azole, luliconazole, requires only once daily application for one week and may improve patient compliance through a more convenient dosing schedule.<xref ref-type="bibr" rid="article-30207.r6">[6]</xref> Ciclopirox olamine is an older topical preparation with a unique mechanism of action compared to the commonly used allylamines and azoles.<xref ref-type="bibr" rid="article-30207.r17">[17]</xref> Recent studies have demonstrated a number of benefits to ciclopirox therapy; however, it remains an underutilized antifungal medication.<xref ref-type="bibr" rid="article-30207.r17">[17]</xref></p>
        <p>Oral preparations exist to manage tinea cruris and are indicated for chronic, recurrent, and recalcitrant disease.<xref ref-type="bibr" rid="article-30207.r1">[1]</xref><xref ref-type="bibr" rid="article-30207.r2">[2]</xref><xref ref-type="bibr" rid="article-30207.r4">[4]</xref><xref ref-type="bibr" rid="article-30207.r6">[6]</xref> Extensive or diffuse rashes and patients with immunocompromise may also require systemic treatments.<xref ref-type="bibr" rid="article-30207.r4">[4]</xref> Stratum corneum penetration and concentration maintenance, keratin adherence, patient tolerance, and a minimal drug interaction profile are hallmarks of the ideal systemic medication for dermatophytoses.<xref ref-type="bibr" rid="article-30207.r4">[4]</xref> Oral terbinafine and itraconazole have favorable characteristics for dermatophyte management and are the most often prescribed.<xref ref-type="bibr" rid="article-30207.r4">[4]</xref><xref ref-type="bibr" rid="article-30207.r15">[15]</xref><xref ref-type="bibr" rid="article-30207.r16">[16]</xref><xref ref-type="bibr" rid="article-30207.r13">[13]</xref>&#x000a0;Fluconazole has demonstrated efficacy in treating tinea cruris; however, it is not preferred due to its poor keratin adherence and prolonged treatment duration.<xref ref-type="bibr" rid="article-30207.r4">[4]</xref> Griseofulvin has similar pharmacokinetic limitations as fluconazole, and it is more appropriately utilized in the management of tinea capitis than tinea cruris.<xref ref-type="bibr" rid="article-30207.r1">[1]</xref><xref ref-type="bibr" rid="article-30207.r4">[4]</xref><xref ref-type="bibr" rid="article-30207.r6">[6]</xref> Due to its potential for hepatotoxicity, oral ketoconazole is no longer recommended for dermatophytoses.<xref ref-type="bibr" rid="article-30207.r1">[1]</xref><xref ref-type="bibr" rid="article-30207.r2">[2]</xref><xref ref-type="bibr" rid="article-30207.r4">[4]</xref><xref ref-type="bibr" rid="article-30207.r15">[15]</xref><xref ref-type="bibr" rid="article-30207.r16">[16]</xref> Topical antifungal therapies may be used as an adjunct in patients requiring systemic treatment. Topical and oral antibiotics can be administered when a secondary bacterial infection is present.<xref ref-type="bibr" rid="article-30207.r3">[3]</xref><xref ref-type="bibr" rid="article-30207.r13">[13]</xref></p>
        <p>A commonly used alternative treatment known as Whitfield's ointment has insufficient evidence of benefit.<xref ref-type="bibr" rid="article-30207.r18">[18]</xref> Nystatin, a frequently utilized treatment for cutaneous candida infections, is ineffective for managing dermatophytoses such as tinea cruris.<xref ref-type="bibr" rid="article-30207.r2">[2]</xref> Combined topical corticosteroid and antifungal therapy remain controversial. Some studies have demonstrated improved cure rates with concomitant steroid and antifungal topical applications; however, these results were based on low-quality evidence.<xref ref-type="bibr" rid="article-30207.r18">[18]</xref> While steroids may improve acute inflammation and itching, they may also fortify dermatophyte's plasma membranes rendering antifungal medications less effective.<xref ref-type="bibr" rid="article-30207.r4">[4]</xref> Steroids also activate fungal metabolism and can potentially facilitate the worsening of the primary infection.<xref ref-type="bibr" rid="article-30207.r4">[4]</xref> Tinea incognito is another possible complication of steroid administration where the typical presentation of tinea is masked, and diagnosis is delayed.<xref ref-type="bibr" rid="article-30207.r1">[1]</xref> Currently, topical steroids are not recommended as part of an evidence-based tinea cruris treatment regimen.<xref ref-type="bibr" rid="article-30207.r2">[2]</xref><xref ref-type="bibr" rid="article-30207.r3">[3]</xref><xref ref-type="bibr" rid="article-30207.r2">[2]</xref><xref ref-type="bibr" rid="article-30207.r18">[18]</xref><xref ref-type="bibr" rid="article-30207.r13">[13]</xref></p>
      </sec>
      <sec id="article-30207.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>The differential diagnosis for tinea cruris includes several other dermatologic conditions affecting the groin with similar presentations.&#x000a0;Candidiasis, erythrasma, psoriasis, and seborrheic dermatitis exhibit comparable signs and symptoms and are most commonly confused with the fungal groin infection.&#x000a0;Unlike tinea cruris, candidal intertrigo frequently affects women, and the rash may involve the scrotum and penis in males.<xref ref-type="bibr" rid="article-30207.r1">[1]</xref><xref ref-type="bibr" rid="article-30207.r2">[2]</xref> Satellite lesions and erythema without central clearing are indicative of candida as opposed to tinea.&#x000a0;The rash of erythrasma lacks an active border and demonstrates coral-red fluorescence on Wood lamp examination.&#x000a0;Psoriasis will likely manifest in other areas in addition to the crural region.&#x000a0;Seborrheic dermatitis presents with greasy scales on an erythematous base.<xref ref-type="bibr" rid="article-30207.r2">[2]</xref></p>
      </sec>
      <sec id="article-30207.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Patients with tinea cruris who undergo an appropriate treatment course experience cure rates ranging from 80 to 90 percent.<xref ref-type="bibr" rid="article-30207.r19">[19]</xref></p>
      </sec>
      <sec id="article-30207.s12" sec-type="Complications">
        <title>Complications</title>
        <p>Failure of therapy and recurrence are the most likely complications of tinea cruris. They have been attributed to reinfection from close contacts, autoinfection from separate body locations, infection by uncommon species such as zoonoses, misdiagnosis, drug resistance, and non-adherence to the management plan.<xref ref-type="bibr" rid="article-30207.r3">[3]</xref> Steroid use may suppress the physical signs of tinea cruris, making the diagnosis more difficult. Also, chronic application can result in skin atrophy and telangiectasias.<xref ref-type="bibr" rid="article-30207.r4">[4]</xref>&#x000a0;Secondary bacterial infection is another potential complication of tinea cruris.<xref ref-type="bibr" rid="article-30207.r3">[3]</xref> Majocchi&#x02019;s granuloma is an uncommon complication of cutaneous fungal infections in which dermatophytes disseminate into the subcutaneous tissue secondary to skin breakdown, immunosuppression, or topical steroid use resulting in a deep, inflammatory disease.<xref ref-type="bibr" rid="article-30207.r3">[3]</xref><xref ref-type="bibr" rid="article-30207.r20">[20]</xref>&#x000a0;A dermatophytid reaction may result in an allergic response&#x000a0;at a separate location from the original tinea site.<xref ref-type="bibr" rid="article-30207.r21">[21]</xref></p>
      </sec>
      <sec id="article-30207.s13" sec-type="Consultations">
        <title>Consultations</title>
        <p>Consultation with dermatology or infectious disease may be warranted in recurrent or recalcitrant cases.<xref ref-type="bibr" rid="article-30207.r3">[3]</xref></p>
      </sec>
      <sec id="article-30207.s14" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Patient education should focus on non-pharmacologic measures to treat and prevent recurrences of tinea cruris. Loose-fitting, non-restrictive garments should be encouraged, and clothing should not be donned until the underlying skin is completely dried.<xref ref-type="bibr" rid="article-30207.r3">[3]</xref> Because autoinfection originating from tinea pedis may occur, patients should avoid walking barefoot, and protective footwear should be used in public facilities.<xref ref-type="bibr" rid="article-30207.r3">[3]</xref><xref ref-type="bibr" rid="article-30207.r13">[13]</xref>&#x000a0;Identification and treatment of potentially infected contacts, whether human or animal, should be undertaken.<xref ref-type="bibr" rid="article-30207.r13">[13]</xref> Self-treatment with over-the-counter antifungals and steroids should be discouraged as this may result in resistant or chronic infections and can hinder a clinician's ability to make an accurate and timely diagnosis.<xref ref-type="bibr" rid="article-30207.r4">[4]</xref></p>
      </sec>
      <sec id="article-30207.s15" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Tinea cruris is a prevalent pathology with a worldwide distribution and an extensive history of affecting human populations. Despite our familiarity with the condition, there has been limited research specific to this subset of dermatophyte infections. Renewed interest has emerged with the development of recalcitrant infections and concern over fungal resistance. Self-treatment with easy-to-access over-the-counter topical antifungal and steroid preparations have been implicated as a probable cause of the observed decrease in treatment efficacy. In the context of fungal resistance, newly developed formulations such as luliconazole and underutilized, older agents like ciclopirox may be beneficial.&#x000a0;</p>
        <p>With regard to corticosteroids, there is conflicting data on the appropriateness of their use for tinea cruris. Current management principles and guidelines label them as mistreatment; however, continued investigations of their utility are underway.&#x000a0;If a practitioner believes topical steroids may benefit a patient, close supervision should be maintained throughout the treatment course with continued consideration of known adverse event potential for the individual and public health outcomes.&#x000a0;</p>
        <p>With an understanding of the changing landscape of this common condition, and by implementing an interprofessional healthcare team approach including primary care clinicians (including PAs and NPs), dermatologists, infectious disease specialists, pharmacists, and nursing, patient care and public health may be improved through targeted, conscientious mycological treatment, patient education, and antifungal stewardship. [Level 2] This interprofessional paradigm should lead to the best outcomes with minimal to no adverse events. [Level 5]</p>
      </sec>
      <sec id="article-30207.s16">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=30207&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=30207">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/infectious-disease/tinea-cruris/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=30207">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/30207/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=30207">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-30207.s17">
        <fig id="article-30207.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Tinea Cruris <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://dermnetnz.org/images">DermNet New Zealand</ext-link></p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="tinea__cruris" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-30207.s18">
        <title>References</title>
        <ref id="article-30207.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gupta</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Chaudhry</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Elewski</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Tinea corporis, tinea cruris, tinea nigra, and piedra.</article-title>
            <source>Dermatol Clin</source>
            <year>2003</year>
            <month>Jul</month>
            <volume>21</volume>
            <issue>3</issue>
            <fpage>395</fpage>
            <page-range>395-400, v</page-range>
            <pub-id pub-id-type="pmid">12956194</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30207.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ely</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Rosenfeld</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Seabury Stone</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Diagnosis and management of tinea infections.</article-title>
            <source>Am Fam Physician</source>
            <year>2014</year>
            <month>Nov</month>
            <day>15</day>
            <volume>90</volume>
            <issue>10</issue>
            <fpage>702</fpage>
            <page-range>702-10</page-range>
            <pub-id pub-id-type="pmid">25403034</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30207.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sahoo</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Mahajan</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Management of tinea corporis, tinea cruris, and tinea pedis: A comprehensive review.</article-title>
            <source>Indian Dermatol Online J</source>
            <year>2016</year>
            <season>Mar-Apr</season>
            <volume>7</volume>
            <issue>2</issue>
            <fpage>77</fpage>
            <page-range>77-86</page-range>
            <pub-id pub-id-type="pmid">27057486</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30207.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Khurana</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sardana</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Chowdhary</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Antifungal resistance in dermatophytes: Recent trends and therapeutic implications.</article-title>
            <source>Fungal Genet Biol</source>
            <year>2019</year>
            <month>Nov</month>
            <volume>132</volume>
            <fpage>103255</fpage>
            <pub-id pub-id-type="pmid">31330295</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30207.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sardana</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kaur</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Arora</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Goyal</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ghunawat</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Is Antifungal Resistance a Cause for Treatment Failure in Dermatophytosis: A Study Focused on Tinea Corporis and Cruris from a Tertiary Centre?</article-title>
            <source>Indian Dermatol Online J</source>
            <year>2018</year>
            <season>Mar-Apr</season>
            <volume>9</volume>
            <issue>2</issue>
            <fpage>90</fpage>
            <page-range>90-95</page-range>
            <pub-id pub-id-type="pmid">29644192</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30207.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gupta</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Foley</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Versteeg</surname>
                <given-names>SG</given-names>
              </name>
            </person-group>
            <article-title>New Antifungal Agents and New Formulations Against Dermatophytes.</article-title>
            <source>Mycopathologia</source>
            <year>2017</year>
            <month>Feb</month>
            <volume>182</volume>
            <issue>1-2</issue>
            <fpage>127</fpage>
            <page-range>127-141</page-range>
            <pub-id pub-id-type="pmid">27502503</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30207.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Odom</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Pathophysiology of dermatophyte infections.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>1993</year>
            <month>May</month>
            <volume>28</volume>
            <issue>5 Pt 1</issue>
            <fpage>S2</fpage>
            <page-range>S2-S7</page-range>
            <pub-id pub-id-type="pmid">8496407</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30207.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nadalo</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Montoya</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hunter-Smith</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>What is the best way to treat tinea cruris?</article-title>
            <source>J Fam Pract</source>
            <year>2006</year>
            <month>Mar</month>
            <volume>55</volume>
            <issue>3</issue>
            <fpage>256</fpage>
            <page-range>256-8</page-range>
            <pub-id pub-id-type="pmid">16510062</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30207.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Singh</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Verma</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Chandra</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Tiwary</surname>
                <given-names>NK</given-names>
              </name>
            </person-group>
            <article-title>Risk factors for chronic and chronic-relapsing tinea corporis, tinea cruris and tinea faciei: Results of a case-control study.</article-title>
            <source>Indian J Dermatol Venereol Leprol</source>
            <year>2019</year>
            <season>Mar-Apr</season>
            <volume>85</volume>
            <issue>2</issue>
            <fpage>197</fpage>
            <page-range>197-200</page-range>
            <pub-id pub-id-type="pmid">30719987</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30207.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ameen</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Epidemiology of superficial fungal infections.</article-title>
            <source>Clin Dermatol</source>
            <year>2010</year>
            <month>Mar</month>
            <day>04</day>
            <volume>28</volume>
            <issue>2</issue>
            <fpage>197</fpage>
            <page-range>197-201</page-range>
            <pub-id pub-id-type="pmid">20347663</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30207.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vena</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Chieco</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Posa</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Garofalo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bosco</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cassano</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Epidemiology of dermatophytoses: retrospective analysis from 2005 to 2010 and comparison with previous data from 1975.</article-title>
            <source>New Microbiol</source>
            <year>2012</year>
            <month>Apr</month>
            <volume>35</volume>
            <issue>2</issue>
            <fpage>207</fpage>
            <page-range>207-13</page-range>
            <pub-id pub-id-type="pmid">22707134</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30207.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Samdani</surname>
                <given-names>AJ</given-names>
              </name>
            </person-group>
            <article-title>Dermatophyte growth and degradation of human stratum corneum in vitro (pathogenesis of dermatophytosis).</article-title>
            <source>J Ayub Med Coll Abbottabad</source>
            <year>2005</year>
            <season>Oct-Dec</season>
            <volume>17</volume>
            <issue>4</issue>
            <fpage>19</fpage>
            <page-range>19-21</page-range>
            <pub-id pub-id-type="pmid">16599028</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30207.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Drake</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Dinehart</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Farmer</surname>
                <given-names>ER</given-names>
              </name>
              <name>
                <surname>Goltz</surname>
                <given-names>RW</given-names>
              </name>
              <name>
                <surname>Graham</surname>
                <given-names>GF</given-names>
              </name>
              <name>
                <surname>Hardinsky</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Lewis</surname>
                <given-names>CW</given-names>
              </name>
              <name>
                <surname>Pariser</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Skouge</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Webster</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Whitaker</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Butler</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Lowery</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Elewski</surname>
                <given-names>BE</given-names>
              </name>
              <name>
                <surname>Elgart</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Jacobs</surname>
                <given-names>PH</given-names>
              </name>
              <name>
                <surname>Lesher</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Scher</surname>
                <given-names>RK</given-names>
              </name>
            </person-group>
            <article-title>Guidelines of care for superficial mycotic infections of the skin: tinea corporis, tinea cruris, tinea faciei, tinea manuum, and tinea pedis. Guidelines/Outcomes Committee. American Academy of Dermatology.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>1996</year>
            <month>Feb</month>
            <volume>34</volume>
            <issue>2 Pt 1</issue>
            <fpage>282</fpage>
            <page-range>282-6</page-range>
            <pub-id pub-id-type="pmid">8642094</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30207.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Raghukumar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ravikumar</surname>
                <given-names>BC</given-names>
              </name>
            </person-group>
            <article-title>Potassium hydroxide mount with cellophane adhesive tape: a method for direct diagnosis of dermatophyte skin infections.</article-title>
            <source>Clin Exp Dermatol</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>43</volume>
            <issue>8</issue>
            <fpage>895</fpage>
            <page-range>895-898</page-range>
            <pub-id pub-id-type="pmid">29845649</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30207.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gupta</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Cooper</surname>
                <given-names>EA</given-names>
              </name>
            </person-group>
            <article-title>Update in antifungal therapy of dermatophytosis.</article-title>
            <source>Mycopathologia</source>
            <year>2008</year>
            <season>Nov-Dec</season>
            <volume>166</volume>
            <issue>5-6</issue>
            <fpage>353</fpage>
            <page-range>353-67</page-range>
            <pub-id pub-id-type="pmid">18478357</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30207.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>van Zuuren</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Fedorowicz</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>El-Gohary</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Evidence-based topical treatments for tinea cruris and tinea corporis: a summary of a Cochrane systematic review.</article-title>
            <source>Br J Dermatol</source>
            <year>2015</year>
            <month>Mar</month>
            <volume>172</volume>
            <issue>3</issue>
            <fpage>616</fpage>
            <page-range>616-41</page-range>
            <pub-id pub-id-type="pmid">25294700</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30207.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sonthalia</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Agrawal</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sehgal</surname>
                <given-names>VN</given-names>
              </name>
            </person-group>
            <article-title>Topical Ciclopirox Olamine 1%: Revisiting a Unique Antifungal.</article-title>
            <source>Indian Dermatol Online J</source>
            <year>2019</year>
            <season>Jul-Aug</season>
            <volume>10</volume>
            <issue>4</issue>
            <fpage>481</fpage>
            <page-range>481-485</page-range>
            <pub-id pub-id-type="pmid">31334080</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30207.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>El-Gohary</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>van Zuuren</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Fedorowicz</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Burgess</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Doney</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Stuart</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Moore</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Little</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Topical antifungal treatments for tinea cruris and tinea corporis.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2014</year>
            <month>Aug</month>
            <day>04</day>
            <volume>2014</volume>
            <issue>8</issue>
            <fpage>CD009992</fpage>
            <pub-id pub-id-type="pmid">25090020</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30207.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hay</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Therapy of Skin, Hair and Nail Fungal Infections.</article-title>
            <source>J Fungi (Basel)</source>
            <year>2018</year>
            <month>Aug</month>
            <day>20</day>
            <volume>4</volume>
            <issue>3</issue>
            <pub-id pub-id-type="pmid">30127244</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30207.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Trocoli Drakensj&#x000f6;</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Vassilaki</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Bradley</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Majocchis Granuloma Caused by Trichophyton mentagrophytes in 2 Immunocompetent Patients.</article-title>
            <source>Actas Dermosifiliogr</source>
            <year>2017</year>
            <season>Jan-Feb</season>
            <volume>108</volume>
            <issue>1</issue>
            <fpage>e6</fpage>
            <page-range>e6-e8</page-range>
            <pub-id pub-id-type="pmid">26952202</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30207.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mayser</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>[Dermatophyte : Current situation].</article-title>
            <source>Hautarzt</source>
            <year>2017</year>
            <month>Apr</month>
            <volume>68</volume>
            <issue>4</issue>
            <fpage>316</fpage>
            <page-range>316-323</page-range>
            <pub-id pub-id-type="pmid">28116455</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
